
    
      This is a Phase III, randomized, multicenter, double-blind, placebo-controlled, study to
      evaluate the efficacy and safety of durvalumab adjuvant therapy compared to placebo in
      patients with completely resected stage II-III NSCLC who have undergone curative intent
      therapy (complete resection Â± neoadjuvant and/or adjuvant therapy), who have no evidence of
      Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1-defined disease recurrence,
      and who become MRD+ during a 96-week surveillance period.
    
  